Tangy Frédéric, Naim Hussein Y
Unité des Virus Lents, CNRS URA 1930, Institut Pasteur, Paris, France.
Viral Immunol. 2005;18(2):317-26. doi: 10.1089/vim.2005.18.317.
Live attenuated RNA viruses make highly efficient vaccines. Among them is the live attenuated measles virus (MV) vaccine that has been given to a very large number of children and has been shown to be highly efficacious and safe. MV vaccine induces a life-long immunity after a single injection or two low-dose injections. It is easily produced on a large scale in most countries and can be distributed at low cost. Reversion to pathogenicity has never been observed with this vaccine. For all of these characteristics, developing of MV vaccine vector as a multivalent vaccine to immunize children against both measles and other infectious agents such as human immunodeficiency virus (HIV), flaviviruses, or malaria might be very promising for worldwide use. As MV vaccine is inexpensive to produce, the generation of recombinant vaccines may remain affordable and attractive for the developing word. In this article, we describe the development of MV vector and present some recent data showing the capacity of recombinant MV vaccine to express various proteins from HIV and West Nile virus. In addition, the ability of recombinant MV to induce specific immune responses against these different pathogens are presented and discussed.
减毒活RNA病毒可制成高效疫苗。其中减毒活麻疹病毒（MV）疫苗已接种给大量儿童，且已证明其高度有效且安全。MV疫苗单次注射或两次低剂量注射后可诱导终身免疫。在大多数国家，它易于大规模生产，且能以低成本分发。该疫苗从未出现过恢复致病性的情况。鉴于所有这些特性，开发MV疫苗载体作为多价疫苗，用于免疫儿童预防麻疹和其他传染病原体，如人类免疫缺陷病毒（HIV）、黄病毒或疟疾，在全球范围内使用可能非常有前景。由于MV疫苗生产成本低廉，重组疫苗的生产对于发展中国家而言可能仍具成本效益且颇具吸引力。在本文中，我们描述了MV载体的研发情况，并展示了一些近期数据，这些数据表明重组MV疫苗能够表达来自HIV和西尼罗河病毒的各种蛋白质。此外，还介绍并讨论了重组MV诱导针对这些不同病原体的特异性免疫反应的能力。
